In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Cytosorbents Corp (NASDAQ: CTSO), with a price target of $15. The company’s shares closed yesterday at $12.90, close to its 52-week high of $13.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 6.4% and a 38.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytosorbents Corp with a $14 average price target, an 8.5% upside from current levels. In a report released today, Cowen & Co. also reiterated a Buy rating on the stock with a $15 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13 and a one-year low of $4.50. Currently, Cytosorbents Corp has an average volume of 338.4K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CTSO in relation to earlier this year. Most recently, in June 2018, Phillip Chan, the President & CEO of CTSO bought 8,000 shares for a total of $30,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
